Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib Treatment

NCT01108705 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

87

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG: Brivanib
DRUG: Placebo

Sponsor

Bristol-Myers Squibb